000			01938 a2200517 4500
005			20250515224748.0
264		0	_c20110131
008			201101s 0 0 eng d
022			_a1432-0843
024	7		_a10.1007/s00280-010-1307-z _2doi
040			_aNLM _beng _cNLM
100	1		_aO'Reilly, Terence
245	0	0	_aEverolimus and PTK/ZK show synergistic growth inhibition in the orthotopic BL16/BL6 murine melanoma model. _h[electronic resource]
260			_bCancer chemotherapy and pharmacology _cJan 2011
300			_a193-200 p. _bdigital
500			_aPublication Type: Journal Article
650	0	4	_aAngiogenesis Inhibitors _xadministration & dosage
650	0	4	_aAnimals
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xadministration & dosage
650	0	4	_aCell Line, Tumor
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aDrug Synergism
650	0	4	_aEverolimus
650	0	4	_aFemale
650	0	4	_aMechanistic Target of Rapamycin Complex 1
650	0	4	_aMelanoma, Experimental _xdrug therapy
650	0	4	_aMice
650	0	4	_aMice, Inbred C57BL
650	0	4	_aModels, Biological
650	0	4	_aMultiprotein Complexes
650	0	4	_aNeoplasm Metastasis
650	0	4	_aPhthalazines _xadministration & dosage
650	0	4	_aProteins _xantagonists & inhibitors
650	0	4	_aPyridines _xadministration & dosage
650	0	4	_aReceptors, Vascular Endothelial Growth Factor _xantagonists & inhibitors
650	0	4	_aSirolimus _xadministration & dosage
650	0	4	_aTOR Serine-Threonine Kinases
700	1		_aLane, Heidi A
700	1		_aWood, Jeanette M
700	1		_aSchnell, Christian
700	1		_aLittlewood-Evans, Amanda
700	1		_aBrueggen, Josef
700	1		_aMcSheehy, Paul M J
773	0		_tCancer chemotherapy and pharmacology _gvol. 67 _gno. 1 _gp. 193-200
856	4	0	_uhttps://doi.org/10.1007/s00280-010-1307-z _zAvailable from publisher's website
999			_c19864436 _d19864436